Skip to main content
Gary Steinberg, MD, Urology, Chicago, IL

GarySteinbergMD

Urology Chicago, IL

Surgical Oncology

Professor and Director Goldstein Urology Bladder Cancer Program NYU Langone Health

Dr. Steinberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Steinberg's full profile

Already have an account?

  • Office

    1725 W Harrison ST, STE 970
    Chicago, IL 60612
    Phone+1 312-947-3447

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Urology, 1987 - 1991
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Surgery, 1985 - 1987
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1985
  • Johns Hopkins University
    Johns Hopkins UniversityB.A., 1981

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1994 - 2026
  • NY State Medical License
    NY State Medical License 2019 - 2024
  • NJ State Medical License
    NJ State Medical License 1991 - 1995
  • MD State Medical License
    MD State Medical License 1988 - 1993
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Best Doctors US News and World Report, 2011
  • Best Doctors in America 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA  
    Siamak Daneshmand, Anne K. Schuckman, Bernard H. Bochner, Michael S. Cookson, Tracy M. Downs, Leonard G. Gomella, H. Barton Grossman, Ashish M. Kamat, Badrinath R. Kon..., Nat. Rev. Urol, 1/23/2014
  • Gender disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation  
    Joshua A. Cohn, M.D., Benjamin Vekhter, Ph.D., Christopher Lyttle, M.S., Gary D. Steinberg, M.D., and Michael C. Large, M.D, Cancer, 1/1/2014
  • Alvimopan, a Peripherally Acting Mu-Opioid Receptor Antagonist, Is Associated With Reduced Costs After Radical Cystectomy? Economic Analysis of a Phase 4 Randomized, C...  
    Teresa L. Kauf, PhD1; Robert S. Svatek, MD2; Gilad Amiel, MD3; Timothy L. Beard, MD4; Sam S. Chang, MD5; Amr Fergany, MD6; R. Jeffrey Karnes, MD7; Michael Koch, MD8; J..., The Journal of Urology, 1/1/2014
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Clinical Evaluation of Cisplatin Sensitivity Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer
    Peter H. O'Donnell, Ilana R. Garcia-Grossman, Hongyuan Cao, Irina Ostrovnaya, Elizabeth R. Plimack, Kelly L. Stratton, Christopher Manschreck, Norm D. Smith, Gary D. S..., GU ASCO Meeting, San Francisco, CA, 1/30/2014
  • Phase I/II study of vesigenurtacel-L (HS-410) or placebo in combination with Bacillus Calmette-Guerin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)
    Steinberg G, Shore N, Karsh L, Bailen J, Woods M, Schoenberg M, Schreiber TH and Price M, Society for Immunotherapy of Cancer Meeting, Washington, DC, 1/7/2014
  • Alvimopan, a peripherally acting mu-opiod receptor antagonist, accelerates gastrointestinal recovery and decreases length of hospital stay after radical cystectomy
    Kamat A, Chang S, Lee C, Amiel G, Beard T, Fergany A, Karnes J, Menon V, Sexton W, Slaton J, Svatek R, Wilson S, Techner L, Bihrle R, Koch M, Steinberg G, AUA meeting, San Diego, CA, 1/7/2013
  • Join now to see all

Lectures

  • Options for bladder cancer patients undergoing radical cystectomy 
    Nashville, TN - 1/23/2014
  • Non-muscle invasive and Muscle invasive bladder cancer 
    Clinica Alemana, Santiago, Chile - 1/13/2014
  • High risk Non Muscle Invasive Bladder Cancer 
    Columbia University, New York, NY - 1/28/2013
  • Join now to see all

Other

  • Bladder Cancer 
    Steinberg GD, Brosman SA, Curti B, et al, eMedicine from WebMD
    http://emedicine.medscape.com/article/438262-overview
    1/29/2011
  • Transurethral Resection of Bladder Tumors 
    Steinberg GD, Sachdeva K, Curti B, Katz MH, Jana BR, eMedicine from WebMD
    http://emedicine.medscape.com/article/1951622-overview
    1/29/2011
  • Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer 
    Steinberg GD, Sachdeva K, Curti B, Katz MH, Jana BR, eMedicine from WebMD
    http://emedicine.medscape.com/article/1950803-overview
    1/29/2011
  • Join now to see all

Press Mentions

  • Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerDecember 5th, 2024
  • Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
    Aura Biosciences Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 12th, 2024
  • Gary Steinberg, MD, on Next Steps for Clinical Development of Bel-Sar in NMIBC
    Gary Steinberg, MD, on Next Steps for Clinical Development of Bel-Sar in NMIBCOctober 30th, 2024
  • Join now to see all